2seventy bio (TSVT) has issued an update.
Philip Gregory, Chief Scientific Officer of 2seventy bio, Inc., will leave the company following the completion of its asset sale to Regeneron Pharmaceuticals. A Release Agreement ensures his equity awards will vest over the next twelve months after his departure. In separate news, Bristol Myers Squibb and 2seventy bio announced a favorable FDA advisory committee vote for Abecma, a drug for multiple myeloma, which will influence the FDA’s decision on the drug’s supplemental Biologics License Application.
Learn more about TSVT stock on TipRanks’ Stock Analysis page.
